Market Overview - The Hong Kong stock market experienced a collective drop in the afternoon, with the Hang Seng Index closing down 0.08% at 24,162.87 points and a total turnover of HKD 250.34 billion [1] - The Hang Seng Tech Index fell by 0.76%, while the Hang Seng China Enterprises Index decreased by 0.15% [1] - CICC noted that despite the need for overall recovery in China, there are structural highlights in the macro and market environment, making Hong Kong stocks advantageous for stable returns and structural opportunities in new consumption, AI technology, and innovative pharmaceuticals [1] Blue Chip Performance - China Hongqiao (01378) led blue-chip stocks with a rise of 4.83% to HKD 15.2, contributing 3.15 points to the Hang Seng Index [2] - BYD (01211) increased by 3.71%, contributing 28.49 points, while Hansoh Pharmaceutical (03692) rose by 3.59% [2] - Li Auto (02015) fell by 2.75%, dragging down the index by 7.25 points, and Galaxy Entertainment (00027) dropped by 2.22%, contributing a decline of 2.57 points [2] Sector Highlights Innovative Pharmaceuticals - The innovative drug sector continued its upward trend, with notable gains from companies like Crystal Pharma (02228) up 16.7% and Lepu Biopharma (02157) up 11.5% [3] - The State Council issued opinions to improve the basic medical insurance drug catalog, which is expected to enhance the demand for innovative drugs [3] - Analysts believe that the biotech sector's valuation recovery is largely complete, with strong market liquidity and robust corporate earnings expected to drive continued interest [3] Aviation Stocks - Major Chinese airlines saw positive performance, with China Eastern Airlines (00670) up 4.08% and China Southern Airlines (01055) up 3.39% [4] - Citigroup maintained a "buy" rating on the three major Chinese airlines, citing a more balanced supply-demand outlook and stable domestic ticket prices [4] - Target prices for China Southern Airlines and China Eastern Airlines were adjusted upward, reflecting positive market sentiment [4] Shipping Sector - The shipping sector benefited from increased trade demand, with Shanghai's export container settlement price index rising by 29.5% [5] - Analysts noted that ongoing tariff uncertainties and economic expectations will influence the sustainability of shipping demand in the coming years [5] Gaming Sector - The gaming sector showed mixed results, with some stocks like Galaxy Entertainment declining while others like SJM Holdings (00880) rose by 6.25% [6] - The Macau government announced the end of operations for several satellite venues by the end of the year, impacting revenue expectations for certain companies [6] Notable Stocks - Dekang Agriculture (02419) reached a new high, closing up 8.3% with significant sales figures reported [7] - New City Development (01030) surged by 7.18% amid news of a planned USD bond issuance [8] - Longpan Technology (02465) rose by 6.47% as interest in solid-state batteries continues to grow [9] New Listings - Rongda Technology (09881) debuted strongly, closing up 42% at HKD 14.2, focusing on AIDC solutions [10] - New Qian'an (02573) also performed well, rising 21.43% with a focus on food additives [11]

Market Overview - The Hang Seng Index closed down 0.08% after fluctuating throughout the day, with a peak of 24,296 points, the highest level since March 20 [1] - The market experienced a significant drop in the afternoon, falling by as much as 178 points to a low of 24,003 points [1] - The total trading volume for the day was 250.34 billion HKD [1] Sector Performance - Strong performance was noted in the aviation, rare earth, and lithium battery sectors, along with a rebound in precious metals [1] - The biopharmaceutical and pharmaceutical outsourcing sectors continued to show strength [1] - Conversely, domestic retail, non-alcoholic beverages, and semiconductor stocks declined, with new consumption concepts and military industry stocks experiencing a pullback [1] Notable Stocks - China Rare Earth (00769.HK) surged over 13%, while China Hongqiao (01378.HK) rose nearly 5% [1] - BYD Company (01211.HK) and Hansoh Pharmaceutical (03692.HK) both increased by over 3.5%, and CSPC Pharmaceutical Group (01093.HK) rose nearly 3% [1] - On the downside, Bruker (00325.HK) and Mixue Group (02097.HK) fell over 6%, while Kingdee International (00268.HK) and Huahong Semiconductor (01347.HK) dropped over 3% [1]

Group 1 - The innovative drug sector in Hong Kong continues to rise, with related ETFs showing significant gains, averaging around 3% in half-day trading and a total transaction amount exceeding 1 billion yuan [1][2] - The Hong Kong Medicine ETF (513200) recorded a half-day transaction amount of 474 million yuan, indicating active trading [1][3] - The number of pharmaceutical companies included in the Hong Kong Stock Connect has reached nearly 100, accounting for over 40% of the total pharmaceutical companies listed in Hong Kong [3] Group 2 - The average holding ratio of the top ten pharmaceutical stocks by Northbound funds is around 40%, reflecting sustained buying interest from mainland investors [3] - The valuation of the Hong Kong pharmaceutical sector has been contracting since mid-2021, with some quality companies' PE ratios nearing historical lows, suggesting limited downside risk for their stock prices [3] - The Hong Kong Medicine ETF (513700) and the Hong Kong Stock Connect Medicine ETF (513200) have seen half-day gains of 3.4% and 3.36%, respectively, with the latter's scale reaching 2.73 billion shares [3][4] Group 3 - The CSI Hong Kong Stock Connect Medical and Health Comprehensive Index selects 50 liquid and large-cap healthcare companies to reflect the overall performance of the sector [3] - Major weighted stocks in the index include Innovent Biologics (11.09%), BeiGene (10.33%), and WuXi Biologics (9.31%), among others [5][6]

金十数据6月10日讯，隔夜美股三大股指涨跌不一，中国金龙指数震荡拉升。港股今早反覆向好，恒指 高开49点报24231点，大市早段好淡争持，一度转跌32点低见24148点，但低位有支持，大市掉头回升， 一度涨115点，再创3月20日后超过两个半月高位，但科指走势偏软。截至收盘，恒指早盘收涨0.33%， 科指早盘收跌0.33%，恒指大市成交额1270.1亿港元。盘面上，航空、内房、内房物管股走强，有色金 属股反弹，生物医药及医药外包概念股持续走强；应用软件、非酒精饮料、半导体股走低，新消费概 念、军工股回调。个股方面，中国稀土(00769.HK)涨17.6%，石药集团(01093.HK)涨超5.3%，中国宏桥 (01378.HK)涨超4.5%，翰森制药(03692.HK)、龙湖集团(00960.HK)均涨3%；布鲁可(00325.HK)跌超 8.5%，蜜雪集团(02097.HK)跌超5.5%，金蝶国际(00268.HK)、华虹半导体(01347.HK)跌2.5%。 港股午评：恒指收涨0.33% 生物医药股受到追捧 ...

Group 1 - The Hang Seng Medical Index ETF has shown active trading with a turnover of 14.61% and a transaction volume of 40.57 million yuan, indicating a vibrant market activity [3] - Over the past two weeks, the Hang Seng Medical Index ETF has experienced a significant growth in scale, increasing by 4.21 million yuan, ranking in the top third among comparable funds [3] - The current price-to-earnings ratio (PE-TTM) of the Hang Seng Medical Healthcare Index is 27.7 times, which is at a historical low, being below 91.86% of the time over the past three years [3] Group 2 - The top ten weighted stocks in the Hang Seng Medical Healthcare Index account for 57.95% of the index, with notable companies including Innovent Biologics, BeiGene, and WuXi Biologics [3] - Recent government policies aim to enhance and improve public health services, including adjustments to the basic medical insurance drug list and the introduction of innovative drug lists for commercial health insurance [3] - Industry experts anticipate that the medical innovation sector is entering a harvest period, with a clear trend of performance and valuation recovery expected in the second half of the year [3] Group 3 - Yangtze Securities highlights that favorable domestic policies are emerging to encourage high-quality innovation, which may drive rapid growth in corporate performance [4] - The valuation levels of domestic innovative drugs are low, with some products showing potential to be the best in their class globally, suggesting a positive outlook for international market expansion [4] - Investors without stock accounts can access investment opportunities in the Hong Kong medical sector through the Hang Seng Medical Index ETF linked fund (018433) [4]

Investment Rating - The report assigns a rating of "Buy" to Hansoh Pharmaceutical (3692 HK) with a target price of HKD 29.30 [6][8]. Core Insights - Hansoh Pharmaceutical has successfully entered into an overseas licensing agreement with Regeneron, which includes an upfront payment of USD 80 million and potential milestone payments of up to USD 1.93 billion, along with royalties on sales [6][8]. - The report highlights the strong performance of the new consumption stocks, particularly the significant price increases of companies like Blok (325 HK) and the mixed performance of Gu Ming (1364 HK) and Mixue Group (2097 HK) after being included in the Hong Kong Stock Connect [3][4]. - The healthcare sector, particularly the biotech companies, has shown robust growth, with the Hang Seng Healthcare Index rising by 4.8%, outperforming the Hang Seng Index [4]. Summary by Sections Macro Dynamics - The new housing transaction volume in major cities has seen a year-on-year decline of 18.1%, indicating a weakening real estate market [2]. Industry Dynamics - The new consumption sector has been positively impacted by the inclusion in the Hong Kong Stock Connect, with notable stock price increases [3]. - The AI sector is gaining traction, with Fourth Paradigm (682 HK) seeing a 9.7% increase due to positive quarterly results and new AI solutions for the healthcare industry [3]. Healthcare Sector - The healthcare index has outperformed the broader market, with significant gains from companies like Innovent Biologics (1801 HK) and others, driven by new drug approvals and clinical trial successes [4]. - The report emphasizes the potential of Hansoh Pharmaceutical's new drug HS-20094, which has completed several Phase II clinical trials and is recognized for its quality by Regeneron [6][8]. Energy Sector - The report suggests a cautious approach towards the new energy sector, with mixed performances observed in solar stocks and a positive outlook for coal-fired power generation due to low coal prices [10][11]. - The nuclear energy sector is expected to benefit from increased demand for uranium, driven by U.S. initiatives to boost domestic nuclear energy production [13][15].

Group 1 - The pharmaceutical sector is experiencing increased activity, with the Tianhong Innovation Drug ETF (517380) rising by 0.30% and trading volume exceeding 11 million yuan, indicating a premium trading environment [1] - Key stocks within the Tianhong Innovation Drug ETF include Kexing Pharmaceutical, Kanglong Chemical, Hansoh Pharmaceutical, and others, with Kexing Pharmaceutical seeing an increase of over 3% [1] - The Tianhong Innovation Drug ETF is the only product tracking the Hang Seng Shanghai-Shenzhen Hong Kong Innovation Drug Selected 50 Index, which includes leading companies in the innovation drug sector [1] Group 2 - The Biopharmaceutical ETF (159859) has risen by 0.27% with a trading volume exceeding 37 million yuan, also indicating a premium trading environment [2] - The Biopharmaceutical ETF closely tracks the Guozheng Biopharmaceutical Index and is the largest product in its category, supported by connecting funds [2] - Recent government policies aim to enhance the sharing of quality medical resources and improve the basic medical insurance drug catalog, which is expected to drive growth for pharmaceutical companies, particularly in the innovation drug sector [2] Group 3 - The National Medical Insurance Administration plans to release the first version of the Class C drug catalog by 2025, focusing on innovative drugs with significant clinical value that are currently not included in the basic insurance catalog [3] - Analysts remain optimistic about the innovation drug sector, overseas expansion, and the clearing of centralized procurement, suggesting that these areas will be key investment themes in the pharmaceutical sector through 2025 [3] - The pharmaceutical market in China is undergoing a period of increasing concentration, with mergers and acquisitions expected to accelerate, highlighting potential growth opportunities in specific segments such as insulin and orthopedics [3]

Core Viewpoint - The innovative pharmaceutical sector, particularly the Hong Kong Stock Connect innovative drug segment, is experiencing significant growth, with the index and major stocks showing strong upward trends [1][3]. Group 1: Market Performance - The Hong Kong Stock Connect innovative drug index (987018) has risen by 1.38%, with key stocks like Tigermed (03347) increasing over 7% and others like Kanglong Chemical (03759) and 3SBio rising over 5% [1]. - The Hong Kong Stock Connect innovative drug ETF (159570) has seen a 2.7% increase, with trading volume surpassing 700 million yuan, marking a historical high [1][3]. - Over the past five days, the Hong Kong Stock Connect innovative drug ETF has attracted a total net inflow of 736 million yuan, averaging 147 million yuan daily [3]. Group 2: Investment Trends - Leverage funds are increasingly being utilized, with the latest financing buy-in for the Hong Kong Stock Connect innovative drug ETF reaching 222 million yuan [3]. - The upcoming American Society of Clinical Oncology (ASCO) annual meeting is expected to showcase a growing number of Chinese pharmaceutical companies, with 73 studies selected for oral presentations in 2025 [3]. Group 3: Sector Analysis - Domestic innovative drugs are gaining competitive strength in the global market, with international investors showing increasing confidence in Chinese pharmaceutical companies [3]. - The Hong Kong Stock Connect innovative drug ETF (159570) has a significant focus on the innovative drug industry, with the top ten holdings accounting for nearly 72% of the total weight [4][5]. - The ETF is characterized by a high concentration in innovative drugs, with an 85% weight in this category, and is considered undervalued compared to historical sales ratios [5].

Group 1 - The core viewpoint of the report is that Zhongtai International has upgraded the rating of Hansoh Pharmaceutical (03692) to "Buy" and raised the target price to HKD 29.30, reflecting positive sales contributions from overseas markets [1] - The sales revenue forecasts for 2025-2027 have been adjusted upward by 0.2%-0.6%, while total revenue forecasts have been increased by 1.2%-3.7%, and net profit forecasts for shareholders have been raised by 1.3%-4.9% [1] - The company has successfully entered into an overseas licensing agreement with Regeneron Pharmaceuticals (REGN.US), which includes an upfront payment of USD 80 million and potential milestone payments of up to USD 1.93 billion [1] Group 2 - The core product Amelot in the oncology sector has received approval in the UK, indicating the company's strong R&D capabilities [2] - Amelot is approved for use as a first-line treatment for adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutations, as well as for patients with EGFRT790M mutation-positive NSCLC [2] - The approval in the UK is seen as a solid foundation for further market entry in the EU, despite cautious short-term sales predictions due to competition from AstraZeneca's drug [2]

2025.06. 09 本文字数：2444，阅读时长大约4分钟 作者 | 第一 财经 王方然 创新药板块再度走强。6月9日，常山药业（300255.SZ）、舒泰神（300204.SZ）、睿智医药 （300149.SZ）、众生药业（002317.SZ）等多只A股涨停。港股的金斯瑞生物科技 （01548.HK）、四环医药（00460.HK）、诺诚健华（09969.HK）等大涨超10%。 记者注意到，这轮"吃药"行情与过往不同，涨幅龙头集中于创新药企业，且港股表现尤为强劲。 爆发并非偶然，而是政策、业绩与资金面多重因素共振的结果。不过，也有机构认为火热行情下暗藏 波动风险，提醒港股短期或面临获利回吐压力。 截至当日收盘，恒生创新药ETF（159316）、港股通医药ETF（513200）分别上涨4.08%、 4.25%。多只个股涨幅较大。当日盘中，三生制药（01530.HK）股价一度涨超10%，最高触及 22.5港元，距离7年前22.631港元的历史高点仅一步之遥。自今年2月以来，三生制药股价从6港元 的位置一路暴涨，涨幅超过260%。金斯瑞生物科技、四环医药、诺诚健华等涨超10%，信达生物 （01801.HK）、康 ...